

Optimising the continuum of care for patients with **ALK+ NSCLC**

12.15pm-1.15pm
Wednesday 15 April 2015
Room A, Palexpo
Geneva, Switzerland

Light refreshments will be served prior to the symposium

Chair's invitation

Dear Colleague

On behalf of the faculty, I am pleased to welcome you to the Pfizer Oncology satellite symposium: **Optimising the continuum of care for patients with ALK+ NSCLC**. The symposium will be held on Wednesday 15 April 2015 at 12.15pm-1.15pm during this year's European Lung Cancer Conference (ELCC) in Geneva, Switzerland.

Identification of anaplastic lymphoma kinase (*ALK*) gene rearrangements as an oncogenic driver, and the approval of the *ALK* inhibitor crizotinib in Europe for patients with previously treated ALK+ NSCLC, has revolutionised the treatment of this disease.

During our symposium, we will follow the clinical journey of a patient diagnosed with ALK+ NSCLC, and discuss how to optimise the continuum of care in this setting. We will also examine the latest clinical trial data for ALK-targeted agents and our faculty will provide their insights into these therapies. Discussion points will include the intracranial activity of crizotinib, treatment beyond progression and future sequencing of ALK inhibitors.

I hope you enjoy what I'm sure will be an informative and engaging symposium.

Tony Mok, Chair

Professor of Clinical Oncology, Li Shu Fun Medical Foundation
The Chinese University of Hong Kong, Hong Kong

Programme

Chair: Tony Mok

- | | |
|--------------|--|
| 12.15 | Welcome and introductions Tony Mok, Chair (Hong Kong) |
| 12.25 | Crizotinib: treatment of choice for ALK+ NSCLC Federico Cappuzzo (Italy) |
| 12.40 | Panel discussion All faculty |
| 12.45 | Understanding disease progression: clinical considerations Nicolas Girard (France) |
| 13.00 | Panel discussion All faculty |
| 13.05 | What should we do if resistance develops? Tony Mok (Hong Kong) |